GEA
LCTX icon

Glen Eagle Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Glen Eagle Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$1.26K – 1020
2021
Q3 		$1.26K Hold
500
– – ﹤0.01% 975
2021
Q2 		$1.43K Hold
500
– – ﹤0.01% 957
2021
Q1 		$1.18K Hold
500
– – ﹤0.01% 929
2020
Q4 		$880 Hold
500
– – ﹤0.01% 916
2020
Q3 		$468 Hold
500
– – ﹤0.01% 888
2020
Q2 		$435 Sell
500
-613
-55% -$540 ﹤0.01% 860
2020
Q1 		$922 Sell
1,113
-750
-40% -$747 ﹤0.01% 759
2019
Q4 		$1.66K Hold
1,863
– – ﹤0.01% 795
2019
Q3 		$1.83K Buy
+1,863
New +$1.93K ﹤0.01% 714

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Glen Eagle Advisors's LCTX Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 500 shares — an estimated $1.26K sold.

Glen Eagle Advisors first reported a position in LCTX in Q3 2019 and held it in 9 quarters. The position peaked at $1.83K in Q3 2019. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

  • Glen Eagle Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 500 Lineage Cell Therapeutics shares in Q4 2021, an estimated $1.26K.
  • Glen Eagle Advisors first reported a position in Lineage Cell Therapeutics in Q3 2019 and held it in 9 quarters.
  • Glen Eagle Advisors's Lineage Cell Therapeutics position peaked at $1.83K in Q3 2019.
  • 124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.